INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 133 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2018. The put-call ratio across all filers is 0.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $649,000 | -39.6% | 18,921 | -86.9% | 0.03% | -40.7% |
| Q3 2019 | $1,075,000 | +149.4% | 143,921 | +333.2% | 0.05% | +125.0% |
| Q2 2019 | $431,000 | +31.8% | 33,221 | +23.9% | 0.02% | +20.0% |
| Q1 2019 | $327,000 | -33.3% | 26,818 | -37.6% | 0.02% | -37.5% |
| Q4 2018 | $490,000 | -42.2% | 42,996 | +10.0% | 0.03% | -17.9% |
| Q3 2018 | $848,000 | -19.7% | 39,096 | -34.6% | 0.04% | -9.3% |
| Q2 2018 | $1,056,000 | -10.0% | 59,796 | -26.2% | 0.04% | -17.3% |
| Q4 2017 | $1,173,000 | -47.3% | 81,010 | -42.6% | 0.05% | -54.4% |
| Q3 2017 | $2,227,000 | +246.9% | 141,157 | +173.1% | 0.11% | +235.3% |
| Q2 2017 | $642,000 | -60.9% | 51,693 | -48.9% | 0.03% | -55.3% |
| Q1 2017 | $1,644,000 | +9.7% | 101,200 | +1.9% | 0.08% | -14.6% |
| Q4 2016 | $1,498,000 | – | 99,300 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |